
Safety
Achieved
Through
Engineering.
We design molecules and therapies to improve clinical efficacy while reducing physical and psychological risks
We design molecules and therapies to improve clinical efficacy while reducing physical and psychological risks
Arcadia Medicine is advancing a pipeline of promising therapeutic candidates designed to address mental health disorders that were previously intractable or inadequately addressed with existing therapeutics
Drug
In Development
Preclinical
Phase I/II
Phase III
PTSD
(Post-Traumatic Stress Disorder)
AM-1002 is a phenethylamine empathogen which has been optimized for use in drug-assisted psychotherapy for patients suffering from PTSD. AM-1002’s composition has been optimized to produce a shorter time course and safer non-neurotoxic drug profile, as compared to MDMA.
MDD
(Major Depressive Disorder)
AM-1004 is a combination (psychoactive-empathogen) product designed for the treatment of major depression. Its profile has been generated to produce fewer negative psychological and physical side effects compared to psilocybin therapy and to have a shorter time course.
SA
(Substance Abuse)
AM-1006 is an internasal low-dose psychoactive product which has been designed to produce a short acting effect for optimized use in a traditional hour-long therapeutic setting.
Arcadia Medicine is advancing a pipeline of promising therapeutic candidates designed to address mental health disorders that were previously intractable or inadequately addressed with existing therapeutics
PRECLINICAL
PTSD (Post-Traumatic Stress Disorder)
AM-1002’s composition has been optimized to produce a shorter time course and safer non-neurotoxic drug profile, as compared to MDMA.
IN DEVELOPMENT
MDD (Major Depressive Disorder)
AM-1004 is a combination (psychoactive-empathogen) product designed for the treatment of major depression. Its profile has been generated to produce fewer negative psychological and physical side effects compared to psilocybin therapy and to have a shorter time course.
IN DEVELOPMENT
SA (Substance Abuse)
AM-1006 is an internasal low-dose psychoactive product which has been designed to produce a short acting effect for optimized use in a traditional hour-long therapeutic setting.
Chief Executive Officer and Founder
Nikita Obidin
Vice President of Regulatory Affairs
Gary Riordan
Chief of Staff
Jaclyn Chau
Strategic Advisor
Sarah Sclarsic
Strategic Advisor
Jamie Heywood
Researcher
Quintin Frerichs
Chief Executive Officer and Founder
Vice President of Regulatory Affairs
Chief of Staff
Strategic Advisor
Strategic Advisor
Researcher